Monthly migraine days, tablet utilization, and quality of life associated with rimegepant-post hoc results from an open label safety study (BHV3000-201)

被引：0
|
作者：
Johnston, K. M. [1 ]
Harris, L. [2 ]
Powell, L. [1 ]
Popoff, E. [3 ]
Coric, V [2 ]
L'Italien, G. J. [2 ]
Schreiber, C. P. [4 ]
机构：
[1] Broadstreet Hlth Econ & Outcomes Res, Vancouver, BC, Canada
[2] Biohaven Pharmaceut Inc, New Haven, CT USA
[3] Broadstreet Hlth Econ & Outcomes Res, Vancouver, BC, Canada
[4] CMH Neurol & Headache Ctr, Bolivar, MO USA
来源：
HEADACHE | 2021年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-144
引用
收藏
页码：132 / 133
页数：2
相关论文
共 50 条
  • [1] Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant - post hoc results from an open label safety study (BHV3000-201)
    Johnston, Karissa
    Harris, Linda
    Powell, Lauren
    Popoff, Evan
    Coric, Vladimir
    L'Italien, Gilbert
    Schreiber, Curtis P.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [2] Monthly Migraine Days, Tablet Utilization, and Quality of Life Associated with Rimegepant - Post Hoc Results from an Open Label Safety Study (BHV3000-201)
    Johnston, K.
    Harris, L.
    Powell, L.
    Popoff, E.
    Coric, V.
    L'Italien, G.
    Schreiber, C. P.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 154 - 154
  • [3] Monthly Migraine Days, Tablet Utilization, and Quality of Life Associated with Rimegepant - Post Hoc Results from an Open Label Safety Study (BHV3000-201)
    Johnston, K.
    Harris, L.
    Powell, L.
    Popoff, E.
    Coric, V.
    L'Italien, G.
    Schreiber, C. P.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 103 - 104
  • [4] Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)
    Karissa Johnston
    Linda Harris
    Lauren Powell
    Evan Popoff
    Vladimir Coric
    Gilbert L’Italien
    Curtis P. Schreiber
    The Journal of Headache and Pain, 2022, 23
  • [5] Is the right way to go in between?Rimegepant as needed provides preventive benefit. A comment on: monthly migraine days, tablet utilization, and quality of life associated with rimegepant—post hoc results from an open label safety study (BHV3000–201)
    Andreas R. Gantenbein
    Andreas Kleinschmidt
    The Journal of Headache and Pain, 24 (1)
  • [6] Acute Treatment with Rimegepant 75 mg Confers Long Term Improvements in Median Time to 30% and 50% Reductions in Monthly Migraine Days - Post Hoc Results from an Open Label Safety Study (BHV3000-201)
    L'Italien, G.
    Popoff, E.
    Johnston, K.
    McGrath, D.
    Conway, C. M.
    Powell, L.
    Harris, L.
    Kowalczyk, N.
    Croop, R.
    Coric, V.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 234 - 234
  • [7] Acute Treatment with Rimegepant 75 mg Confers Long Term Improvements in Median Time to 30% and 50% Reductions in Monthly Migraine Days - Post Hoc Results from an Open Label Safety Study (BHV3000-201)
    L'Italien, G.
    Popoff, E.
    Johnston, K.
    McGrath, D.
    Conway, C. M.
    Powell, L.
    Harris, L.
    Kowalczyk, N.
    Croop, R.
    Coric, V.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 2):
  • [8] Acute treatment with rimegepant 75 mg confers long term improvements in median time to 30% and 50% reductions in monthly migraine days-Post hoc results from an open label safety study (BHV3000-201)
    L'Italien, G. J.
    Popoff, E.
    Kowalczyk, N.
    Harris, L.
    Powell, L.
    Johnston, K. M.
    Croop, R.
    Coric, V
    Lipton, R. B.
    HEADACHE, 2021, 61 : 110 - 110
  • [9] Acute Treatment of Migraine with Oral Rimegepant 75 mg Improves Health Related Quality of Life: Results from a Long-Term, Open-Label Safety Study (BHV3000-201)
    Harris, Linda
    L'Italien, Gilbert
    Croop, Robert
    Stock, Elyse
    Thiry, Alexandra
    Cowrie, Kate
    Lovegren, Meghan
    Jensen, Christopher
    Coric, Vladimir
    Lipton, Richard
    NEUROLOGY, 2020, 94 (15)
  • [10] Acute Treatment of Migraine with Oral Rimegepant 75 Mg Improves Health Related Quality of Life: Results from a Long-term, Open-label Safety Study (BHV3000-201)
    Harris, L.
    L'Italien, G. J.
    Croop, R.
    Stock, E. G.
    Thiry, A. C.
    Lovegren, M.
    Jensen, C. M.
    Coric, V
    Lipton, R. B.
    HEADACHE, 2020, 60 : 97 - 98
12345